Theriva Biologics, Inc.SEC Filings
|
|
All SEC filings by Theriva Biologics, Inc. (TOVX) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 11, 2026 | |
| ARS | Annual report to shareholders | Jun 29, 2026 | ||
| 10-Q | Quarterly report | View Diff | May 5, 2026 | |
| 10-K | Annual report | View Diff | Mar 12, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 12, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 11, 2025 | |
| ARS | Annual report to shareholders | Jul 9, 2025 | ||
| 10-Q | Quarterly report | View Diff | May 14, 2025 | |
| 10-K | Annual report | View Diff | Mar 6, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 12, 2024 |
Events
| 8-K | Biologics Reports Second Quarter 2026 Operational Highlightsand Financial Results | Aug 11, 2026 | ||
| 8-K | Regulation Fd Disclosure | Aug 6, 2026 | ||
| 8-K | Current report | Aug 4, 2026 | ||
| 8-K | Regulation Fd Disclosure | Jul 7, 2026 | ||
| 8-K | Current report | Jun 11, 2026 | ||
| 8-K | Current report | Jun 5, 2026 | ||
| 8-K | Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results | May 5, 2026 | ||
| 8-K | Regulation Fd Disclosure | Apr 17, 2026 | ||
| 8-K | Other Events | Apr 9, 2026 | ||
| 8-K | Regulation Fd Disclosure | Mar 23, 2026 |
Registrations and Prospectuses
| S-8 | Registration of securities for employees | Aug 24, 2026 | ||
| 424B5 | Prospectus supplement for primary offering | Dec 3, 2025 | ||
| S-3 | Shelf registration | View Diff | Nov 7, 2025 | |
| 424B5 | Prospectus supplement for primary offering | Oct 29, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 24, 2025 | ||
| D | $13.11 Mm in Options / Securities to Be Acquired, Sold $13.11 Mm, 10 Investors | Oct 23, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 16, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 16, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 16, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 16, 2025 |
Proxies
| DEF 14A | Definitive proxy | View Diff | Jun 29, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | Jun 18, 2026 | |
| DEF 14A | Definitive proxy | View Diff | Apr 30, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | Apr 20, 2026 | |
| DEF 14A | Definitive proxy | View Diff | Mar 16, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | Mar 4, 2026 | |
| DEF 14A | Definitive proxy | View Diff | Jan 6, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | Dec 23, 2025 | |
| DEFA14A | Additional proxy soliciting materials | Nov 12, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Nov 10, 2025 |
Other
| EFFECT | Notice of effectiveness | Dec 3, 2025 | ||
| EFFECT | Notice of effectiveness | May 8, 2025 | ||
| CORRESP | Correspondence with SEC | May 5, 2025 | ||
| CORRESP | Correspondence with SEC | May 5, 2025 | ||
| CORRESP | Correspondence with SEC | Jan 23, 2025 | ||
| CORRESP | Correspondence with SEC | Jan 23, 2025 | ||
| CORRESP | Correspondence with SEC | Jan 21, 2025 | ||
| CORRESP | Correspondence with SEC | Jan 21, 2025 | ||
| EFFECT | Notice of effectiveness | Sep 26, 2024 | ||
| EFFECT | Notice of effectiveness | Sep 26, 2024 |
Ownership
| 4 | Steven a Shallcross | Jan 6, 2026 | ||
| 4 | John J Monahan | Jan 6, 2026 | ||
| 4 | Jeffrey J Kraws | Jan 6, 2026 | ||
| 4 | Jeffrey Alan Wolf | Jan 6, 2026 | ||
| SC 13G | Theriva Biologics, Inc. | Nov 10, 2025 | ||
| SC 13G/A | Theriva Biologics, Inc. | Oct 21, 2025 | ||
| SC 13G | Theriva Biologics, Inc. | Jul 31, 2025 | ||
| 4 | Jeffrey Alan Wolf | May 1, 2025 | ||
| 4 | Steven a Shallcross | May 1, 2025 | ||
| 4 | John J Monahan | May 1, 2025 |